IOVANCE BIOTHERAPEUTICS, INC. 4

COO Igor Bilinsky had 7,813 RSUs vest into common stock and 3,976 shares withheld for taxes at $8.70 per share, resulting in 142,074 Iovance Biotherapeutics shares owned directly.

On September 8, 2026, Igor Bilinsky, Chief Operating Officer of Iovance Biotherapeutics, Inc., had 7,813 restricted stock units vest into an equivalent number of common shares, and simultaneously 3,976 of those shares were withheld by the company at an implied price of $8.70 per share to satisfy mandatory tax withholding obligations, leaving him with 142,074 shares of common stock held directly after the transactions. These events reflect routine equity compensation activity (RSU vesting and related tax withholding) rather than any open-market purchase or sale, and do not indicate a discretionary change in Bilinsky’s economic exposure to Iovance stock. The remaining RSUs from the March 5, 2025 grant will continue to vest in equal quarterly installments.

Filing Facts

CIK

1425205

Ticker

IOVA

Form

4

Source Type

fda

Accession

0001104659-26-106750

Alert Tier

5